Susan A. Galel
Stanford University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Susan A. Galel.
Transfusion | 2009
Magali J. Fontaine; Yenho T. Chung; William M. Rogers; Harry D. Sussmann; Peter Quach; Susan A. Galel; Lawrence T. Goodnough; Feryal Erhun
BACKGROUND: Blood centers and hospital transfusion services are challenged with maintaining an adequate platelet (PLT) inventory to minimize the number of outdated units without risking a major shortage. A novel approach to inventory management was established at our institution through a collaboration between the Stanford University Medical Center (SUMC) Transfusion Service, the Stanford Blood Center (SBC), and the Department of Management Science and Engineering.
Transfusion | 2002
Susan A. Galel; D. Michael Strong; Gary E. Tegtmeier; Paul V. Holland; I.K. Kuramoto; Marti Kemper; Larry Pietrelli; James Gallarda
BACKGROUND: Two HCV antibody tests (EIA 2.0 [EIA2], Abbott; and the Version 3.0 ELISA [EIA3], Ortho) are currently licensed for screening of US blood donors. Testing of donors for HCV RNA allows comparison of the sensitivities of the two antibody‐screening assays.
Transfusion | 2011
Magali J. Fontaine; Jenny Kuo; Ge Chen; Susan A. Galel; Evelyn Miller; Flavia Sequeira; Maurene Viele; Lawrence T. Goodnough; Dolly B. Tyan
BACKGROUND: Immune refractoriness to platelet (PLT) transfusion is primarily due to HLA antibody. Patients at our institution are identified as refractory due to HLA by a Luminex‐based immunoglobulin (Ig)G–single‐antigen‐bead (SAB) assay, but in highly sensitized patients, antigen‐negative compatible donors cannot be found due to the high sensitivity of the IgG‐SAB method. We developed an assay that detects only HLA antibodies binding the first complement component (C1q). We hypothesized that the C1q‐SAB method might be more relevant than the IgG‐SAB method because the antibodies identified may activate the complement cascade causing PLT destruction.
Transfusion | 2000
Delia Menozzi; Troy Udulutch; Augusto E. Llosa; Susan A. Galel
BACKGROUND: In 1998, the FDA recommended look‐back for HCV. The recommendation was initially limited, however, to donors who reacted on a multiantigen HCV screening test and to components collected since January 1, 1988. A lookback program was extended to include donors who reacted on the first‐generation (single‐antigen) HCV screening test and who were positive on a supplemental assay (RIBA‐1 or ‐2) and all components for which transfusion records could be found (back to 1978).
Transfusion | 2014
Jonathan Hughes; Magali J. Fontaine; Christopher L. Gonzalez; Arlene G. Layon; Lawrence T. Goodnough; Susan A. Galel
Documented transfusion‐associated hepatitis A (TAHA) is rare, and blood donors in the United States are not routinely screened for this infection. We report a case of TAHA associated with a donation made 8 days after a donor returned from a trip to South America.
Emerging Infectious Diseases | 2017
Michelle S. Chevalier; Brad J. Biggerstaff; Sridhar V. Basavaraju; M. Cheryl Bañez Ocfemia; Jose O. Alsina; Consuelo Climent-Peris; Robin R. Moseley; Koo-Whang Chung; Brenda Rivera-Garcia; Melissa Bello-Pagan; Lisa Lee Pate; Susan A. Galel; Phillip C. Williamson; Matthew J. Kuehnert
Puerto Rico has been heavily impacted by Zika virus, a mosquitoborne flavivirus that emerged in the Americas during 2015. Although most persons with Zika virus show no symptoms, the virus can cause neurologic and other complications, including fetal microcephaly. Local Zika virus transmission in Puerto Rico has been reported since December 2015. To prevent transfusion-associated transmission, local blood collection ceased in March 2016 but resumed in April 2016 after Zika virus screening of blood donations became available. Using data from screening of blood donations collected by the 2 largest blood centers in Puerto Rico during April 3–August 12, 2016, and assuming a 9.9-day duration of viremia, we estimated that 469,321 persons in Puerto Rico were infected during this period, for an estimated cumulative incidence of 12.9%. Results from blood donation screening during arboviral outbreaks can supplement routine clinical and surveillance data for improved targeting of prevention efforts.
Transfusion | 2013
Lisa Lee Pate; Jessica C. Myers; Jonathan P. Palma; Maurene Viele; Susan A. Galel; Zenaida Ferrer; Christopher L. Gonzalez; William E. Benitz; George Garratty; Magali J. Fontaine
The Gerbich (Ge) blood group system consists of 11 antigens carried on red blood cell (RBC) membrane glycophorins C and D; of these, Ge:3 antigen is of high prevalence, and the anti‐Ge3 is found to be clinically significant.
Transfusion | 2008
Susan A. Galel; Jan Webster; Lurimer Roa
BACKGROUND: Minipool (MP) screening for West Nile virus (WNV) RNA may fail to detect presumptive viremic donations (PVDs) detectable by individual donation screening (IDS). Most blood centers switch collection regions to IDS when PVD detection by MP screening reaches a certain frequency. Use of IDS for all donations during WNV season was assessed during a clinical trial of the Roche cobas TaqScreen WNV test. Also evaluated was whether PVD detection reliably identifies regions that should be targeted for IDS.
Transfusion | 2015
Magali J. Fontaine; Jan Webster; Samantha Gomez; Tho D. Pham; Lawrence T. Goodnough; Susan A. Galel
Plasma volume reduction (PVR) may reduce the risk of hemolysis associated with transfusion of plateletpheresis blood products (PLTs) containing ABO‐incompatible plasma. But PVR may delay PLT issue. In collaboration with our blood donor center we evaluated an automated screen of PLT for high‐titer ABO antibody and to apply PVR to high‐titer PLTs.
Transfusion | 2012
Susan A. Galel; Juliana Gaitan; Darlene T. Yu; Lorna L. Tolentino; Jan Webster; Elaine Sugasawara; Jo Ann Wilson; Cynthia Boone; Patricia Lendio
BACKGROUND: The Trima Accel displays a “verify WBCs” message if the plateletpheresis product (PLT) may not be leukoreduced (LR). Most blood banks require sensitive white blood cell (WBC) testing of these PLTs by flow or Nageotte. We evaluated how often these PLTs were non‐LR by European or US Food and Drug Administration (FDA) criteria and whether sensitive WBC testing is necessary.